Q2 2024 United Therapeutics Corp Earnings Call Transcript
Key Points
- United Therapeutics Corp (UTHR) reported record revenue of $715 million for the second quarter of 2024, marking a 20% growth from the same period in 2023.
- The company experienced meaningful worldwide revenue growth across all key products, including Tyvaso, Orenitram, Remodulin, and Unituxin.
- Tyvaso revenue increased by 25% year-over-year, driven by continued uptake of Tyvaso DPI, price increases, and increased commercial utilization.
- Orenitram achieved record revenue of $107 million, representing a 13% growth from the previous year, supported by increased commercial utilization and pricing.
- The company has a strategic focus on three waves of success: current market-leading products, next-generation products, and an organ manufacturing business with transformative potential.
- The company faces uncertainty in its second wave of success, particularly with Tyvaso for pulmonary fibrosis and Ralinepag for PAH, due to the unpredictability of clinical trial outcomes.
- There is a modest decline in patient access program utilization for Tyvaso DPI and Orenitram, which could impact future growth.
- The company is not immune to potential future impacts from the Inflation Reduction Act, although current products are not on the list for price negotiation.
- The organ manufacturing business, while promising, still requires significant work to achieve FDA approval and quantity production.
- The success of the TETON trial for pulmonary fibrosis is critical, with high stakes as it could more than double the current $3 billion revenue run rate.
Good morning, everyone, and welcome to the United Therapeutics Corporation second-quarter 2024 earnings webcast. My name is Cole, and I'll be your conference operator today. (Operator Instructions) And please note that this call is being recorded. I would now like to turn the webcast over to Dewey Steadman, Head of Investor Relations, at United Therapeutics. Please go ahead.
Yes. Thank you, Cole. Good morning. It's my pleasure to welcome you to the United Therapeutics Corporation second-quarter 2024 earnings webcast.
Remarks we make today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements. Remarks today may discuss the progress and results of clinical trials
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
